Teva Pharmaceutical Industries Ltd. (TEVA) to Issue Quarterly Dividend of $0.34 on December 20th
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced a quarterly dividend on Tuesday, November 15th. Stockholders of record on Monday, December 5th will be paid a dividend of 0.34 per share on Tuesday, December 20th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.56%. The ex-dividend date is Thursday, December 1st.
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at 38.21 on Friday. The firm has a market cap of $38.78 billion, a PE ratio of 22.23 and a beta of 0.73. The stock’s 50 day moving average is $41.56 and its 200-day moving average is $49.24. Teva Pharmaceutical Industries has a 52 week low of $37.12 and a 52 week high of $66.55.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, topping the Zacks’ consensus estimate of $1.29 by $0.02. Teva Pharmaceutical Industries had a return on equity of 16.75% and a net margin of 8.81%. The business earned $5.56 billion during the quarter, compared to the consensus estimate of $5.71 billion. During the same period in the previous year, the company posted $1.35 earnings per share. The business’s revenue for the quarter was up 15.3% on a year-over-year basis. On average, equities analysts predict that Teva Pharmaceutical Industries will post $5.14 EPS for the current fiscal year.
Hedge funds have recently bought and sold shares of the stock. WFG Advisors LP raised its stake in Teva Pharmaceutical Industries by 14.0% in the second quarter. WFG Advisors LP now owns 2,080 shares of the company’s stock worth $104,000 after buying an additional 256 shares during the last quarter. Citizens Financial Group Inc RI raised its stake in Teva Pharmaceutical Industries by 17.1% in the second quarter. Citizens Financial Group Inc RI now owns 2,398 shares of the company’s stock worth $121,000 after buying an additional 351 shares during the last quarter. Krilogy Financial LLC raised its stake in Teva Pharmaceutical Industries by 1.0% in the second quarter. Krilogy Financial LLC now owns 2,635 shares of the company’s stock worth $132,000 after buying an additional 25 shares during the last quarter. SevenBridge Financial Group LLC bought a new stake in Teva Pharmaceutical Industries during the second quarter worth approximately $159,000. Finally, WESPAC Advisors SoCal LLC raised its stake in Teva Pharmaceutical Industries by 1.4% in the second quarter. WESPAC Advisors SoCal LLC now owns 3,550 shares of the company’s stock worth $178,000 after buying an additional 50 shares during the last quarter. 63.16% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries Ltd. (TEVA) to Issue Quarterly Dividend of $0.34 on December 20th” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2016/11/26/teva-pharmaceutical-industries-ltd-teva-to-issue-quarterly-dividend-of-0-34-on-december-20th.html.
TEVA has been the subject of a number of research analyst reports. Mizuho reaffirmed a “buy” rating and issued a $70.00 price target (down from $75.00) on shares of Teva Pharmaceutical Industries in a report on Friday, August 5th. Leerink Swann reaffirmed an “outperform” rating and issued a $66.00 price target on shares of Teva Pharmaceutical Industries in a report on Tuesday, August 16th. Guggenheim reaffirmed a “buy” rating and issued a $80.00 price target on shares of Teva Pharmaceutical Industries in a report on Monday, August 15th. Piper Jaffray Cos. reaffirmed a “neutral” rating and issued a $57.00 price target (up from $55.00) on shares of Teva Pharmaceutical Industries in a report on Monday, August 8th. Finally, Oppenheimer Holdings Inc. downgraded Teva Pharmaceutical Industries from an “outperform” rating to a “market perform” rating and set a $70.29 price target for the company. in a report on Friday, August 5th. Thirteen research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries currently has a consensus rating of “Buy” and an average price target of $60.00.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.
Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.